Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vysis files 510(k)s for CML, bone marrow transplant tests, lands broad FISH patent.

This article was originally published in The Gray Sheet

Executive Summary

VYSIS 510(K)s FOR CEP CML, BONE MARROW TRANSPLANT MONITORING TESTS utilizing fluorescence in situ hybridization technology were submitted to FDA July 31 and Aug. 31, respectively, the company says. Both products are chromosome enumeration probes designed to evaluate and count specific chromosomes in metaphases and interphase nuclei. CEP 8, the prognostic indicator and monitoring probe for chronic myelogenous leukemia, detects copies of chromosome 8; the presence of a third copy indicates a poor prognosis. CEP XY monitors sex chromosomes in the blood of a patient following a bone marrow transplant from a patient of the opposite sex.

You may also be interested in...

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.


ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

Start-Up Snapshot: Nanomedic’s Electro-Spinning, Portable Wound Care Device

At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts